Contrasting Futu (NASDAQ:FUTU) and Dominari (NASDAQ:DOMH)

Dominari (NASDAQ:DOMH) and Futu (NASDAQ:FUTU) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Risk and Volatility

Dominari has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Futu has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.

Valuation & Earnings

This table compares Dominari and Futu”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$9.51 million	1.16	-$22.88 million	($4.64)	-0.40
Futu	$10.75 billion	0.84	$548.14 million	$3.78	17.34

Futu has higher revenue and earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Futu, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dominari and Futu’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dominari	-231.55%	-31.02%	-28.13%
Futu	39.27%	16.77%	4.00%

Analyst Ratings

This is a summary of current recommendations and price targets for Dominari and Futu, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	0	0	0	0	N/A
Futu	0	1	6	0	2.86

Futu has a consensus target price of $71.57, suggesting a potential upside of 9.22%. Given Futu’s higher possible upside, analysts clearly believe Futu is more favorable than Dominari.

Institutional and Insider Ownership

42.5% of Dominari shares are held by institutional investors. 9.7% of Dominari shares are held by company insiders. Comparatively, 35.2% of Futu shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Futu beats Dominari on 10 of the 13 factors compared between the two stocks.

About Dominari

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

About Futu

Futu Holdings Limited provides digitalized securities brokerage and wealth management product distribution service in Hong Kong and internationally. It offers online financial services, including securities and derivative trades brokerage, margin financing and fund distribution services through its Futubull and Moomoo digital platforms. The company also provides financial information and online community services; online wealth management services under the Money Plus brand name through its Futubull and moomoo platforms, which provides its client access to mutual funds, private funds, bonds, structured products, and other wealth management products; market data and information services; and NiuNiu Community, which serves as an open forum for users and clients to share insights, ask questions, and exchange ideas. Futu Holdings Limited was founded in 2007 and is headquartered in Sheung Wan, Hong Kong.